Set as Homepage - Bookmark This Page   
You are here:Home >Research >Immix... recnac latceroloc ni 011-XMI r Content

Immix... recnac latceroloc ni 011-XMI r

Source: Editor: ResearchDate: 2025-06-10 10:16:25
Immix Biopharma (NASDAQ:IMMX) reported early interim data from a phase 1b/2a trial of IMX-110 in combination with Novartis (NYSE:NVS) and BeiGene's (NASDAQ:BGNE) tislelizumab to treat patients with ad... Stay informed with the latest.

1.7292s , 6836.96875 kb

Copyright © 2025 Powered by Immix... recnac latceroloc ni 011-XMI r,  

sitemap

Top